Sensus Healthcare Inc Stock Price, News & Analysis

Sensus Healthcare (SRTS) reported strong Q3 2024 financial results with revenues more than doubling to $8.8 million compared to $3.9 million in Q3 2023. The company achieved net income of $1.2 million ($0.07 per diluted share) versus a net loss of $1.5 million in the prior year. They shipped 27 systems during the quarter and signed a significant Fair Deal Agreement with Platinum Dermatology, a network of 130 dermatology clinics. The company maintained a strong financial position with $22.6 million in cash and no debt. Gross profit margin improved to 59.3% from 51.0% year-over-year.

Sensus Healthcare (Nasdaq: SRTS), a medical device company focused on non-invasive treatments, announces its upcoming Third Quarter 2024 financial results conference call scheduled for November 14, 2024, at 4:30 p.m. Eastern time. Management will discuss Q3 2024 financial results, provide business updates, and review recent and upcoming milestones. The call will be accessible via pre-registration or direct dial-in, with a replay available until December 14, 2024. A webcast will also be available through the company's website.

Sensus Healthcare (Nasdaq: SRTS) has shipped an SRT system to Providence Swedish Hospital in Seattle, marking its latest success in expanding to community hospital oncology departments. The sale highlights growing interest in superficial radiotherapy (SRT) for treating non-melanoma skin cancer and keloids on an outpatient basis.

Dr. Christopher Loiselle, Medical Director of Radiation Oncology at Swedish Cancer Institute, praised the SRT system as state-of-the-art for treating skin cancers and other superficial conditions. Joe Sardano, CEO of Sensus Healthcare, expressed delight in Providence Swedish Hospital's recognition of SRT benefits and noted increasing inquiries from hospitals nationwide about offering non-invasive skin cancer treatments.

Sensus Healthcare (SRTS) reported strong Q2 2024 financial results, with revenues doubling to $9.2 million compared to Q4 2023. The company achieved net income of $1.6 million ($0.10 per diluted share) and positive Adjusted EBITDA of $2.1 million. Key highlights include:

- Shipped 23 systems, including 3 SRT-100 units to Asia
- Signed 15 'Fair Deal Agreements' for SRT-100 Vision units
- Ended Q2 with $19 million in cash and no debt
- Accounts receivable increased to $18.3 million

The company's growth was driven by higher superficial radiotherapy unit sales and international expansion efforts, particularly in Asia. Management expects the Fair Deal Agreement program to generate recurring revenue starting in 2025.

Sensus Healthcare (Nasdaq: SRTS) has announced a conference call scheduled for Thursday, August 8, 2024, at 4:30 p.m. Eastern time to discuss its second quarter 2024 financial results and provide a business update. The company, which specializes in non-invasive treatments for oncological and non-oncological conditions, encourages participants to pre-register for the call. Those unable to pre-register can dial in directly. The call will also be webcast live and accessible through the company's website. A telephone replay will be available until September 8th, and an archived webcast will be accessible in the Investor Relations section of the website.

Sensus Healthcare (Nasdaq: SRTS), a medical device company specializing in non-invasive treatments for oncological and non-oncological conditions, has announced its upcoming second quarter 2024 financial results and business update conference call. The call is scheduled for Thursday, August 8, 2024, at 4:30 p.m. Eastern time.

Key points:

• Management will discuss Q2 2024 financial results
• A business update and discussion on recent and upcoming milestones will be provided
• Participants can pre-register for the call or dial in directly
• A webcast will be available on the company's Investor Relations website
• A telephone replay will be accessible until September 8th

Sensus Healthcare reported a strong first-quarter financial performance with revenues up over three-fold compared to the previous year. Revenues were $10.7 million, net income was $2.3 million, and adjusted EBITDA was $3.0 million. The company launched a recurring revenue program, the 'Fair Deal Agreement', to complement its fair market value lease program. Sensus Healthcare showcased its products at key industry events and announced significant sales and developments, including a U.S. patent for SRT-100 Vision System and international sales.

Sensus Healthcare, Inc. announces the sale of an SRT-100 system to the Veterinary Specialist Referral Center in Tel Aviv, marking the first veterinary commercial sale of the device outside the U.S. This system will provide gentler radiotherapy to treat tumors in dogs and cats. The Knowledge Farm is the largest private Veterinary Specialty Referral Center in Israel, employing over 20 specialists and 30 veterinary technicians. The SRT-100 system has previously been acquired by Colorado State University for treating companion animals and conducting studies on equine ophthalmic tumors.

Sensus Healthcare, Inc. announces the sale of the first SRT-100 Vision™ system in Asia to Far Eastern Memorial Hospital in Taiwan. The hospital plans to conduct research on new indications for the system, potentially leading to global label expansion. The company is optimistic about future sales in the region and emphasizes the importance of this sale. The SRT-100 Vision system utilizes image-guided ultrasound technology and has seen recent enhancements for improved clinical outcomes. Additionally, Sensus Healthcare will host a conference call on May 9, 2024, to discuss first-quarter financial results and provide business updates.